A multinational assessment of direct and indirect costs from a survey of patients with idiopathic pulmonary fibrosis (IPF)

Previous PostSolutions to the comparator question in the absence of licensed comparators? A retrospective analysis of orphan drug and gene therapy reimbursement in EU5 markets